TY - JOUR
T1 - Future trends in patient-reported outcomes assessment for patients with advanced-stage lung cancer receiving targeted therapy
AU - Eton, David T.
AU - Yost, Kathleen J.
AU - Cella, David
N1 - Funding Information:
Funding for this manuscript was provided by Pfizer, Inc.
PY - 2006/9
Y1 - 2006/9
N2 - Recent advances in cancer cell biology have led to the development of therapeutic agents that target pathways critical to the development and progression of disease. These so-called "targeted therapies" might offer patients a more tolerable alternative to traditional systemic chemotherapy that often achieves therapeutic benefit at the cost of debilitating side effects. Several targeted agents have been recently tested in clinical trials of advanced-stage lung cancer. As interest in these therapies grows, an understanding of their impact on the patient's well-being will be important. Patient-reported outcome measures such as formal assessments of health-related quality of life and disease symptoms provide a useful means for addressing the impact of therapy from the perspective of the patient. We summarize the most commonly used measures of health-related quality of life in clinical trials of advanced-stage lung cancer. Although existing measurement systems do provide adequate coverage of many important patient-related outcome issues, the advent of targeted therapies in advanced-stage lung cancer does expose several measurement gaps. We highlight some of these gaps by reviewing a representative sample of recently conducted clinical trials of targeted lung cancer therapy and offer insight as to how these gaps can be filled. We also briefly discuss a set of issues unique to patients receiving targeted therapy (eg, perceptions of treatment efficacy, treatment compliance, patient satisfaction, and treatment convenience) and consider a few methodologic concerns unique to patients with advanced cancer.
AB - Recent advances in cancer cell biology have led to the development of therapeutic agents that target pathways critical to the development and progression of disease. These so-called "targeted therapies" might offer patients a more tolerable alternative to traditional systemic chemotherapy that often achieves therapeutic benefit at the cost of debilitating side effects. Several targeted agents have been recently tested in clinical trials of advanced-stage lung cancer. As interest in these therapies grows, an understanding of their impact on the patient's well-being will be important. Patient-reported outcome measures such as formal assessments of health-related quality of life and disease symptoms provide a useful means for addressing the impact of therapy from the perspective of the patient. We summarize the most commonly used measures of health-related quality of life in clinical trials of advanced-stage lung cancer. Although existing measurement systems do provide adequate coverage of many important patient-related outcome issues, the advent of targeted therapies in advanced-stage lung cancer does expose several measurement gaps. We highlight some of these gaps by reviewing a representative sample of recently conducted clinical trials of targeted lung cancer therapy and offer insight as to how these gaps can be filled. We also briefly discuss a set of issues unique to patients receiving targeted therapy (eg, perceptions of treatment efficacy, treatment compliance, patient satisfaction, and treatment convenience) and consider a few methodologic concerns unique to patients with advanced cancer.
KW - Functional assessment of cancer therapy
KW - Hospital anxiety and depression scale
KW - Lung cancer symptom scale
KW - Quality of life
KW - Rotterdam symptom checklist
KW - Symptoms
UR - http://www.scopus.com/inward/record.url?scp=33750176007&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750176007&partnerID=8YFLogxK
U2 - 10.3816/CLC.2006.n.037
DO - 10.3816/CLC.2006.n.037
M3 - Review article
C2 - 17026810
AN - SCOPUS:33750176007
SN - 1525-7304
VL - 8
SP - 99
EP - 109
JO - Clinical lung cancer
JF - Clinical lung cancer
IS - 2
ER -